MYDECINE Aktie

 

The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2025. Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2025. ISIN Name CA80013R2063 SANDSTORM GOLD CA01559R4008 ALGERNON PHARMACEUT. A CA0682943059 BAROYECA GOLD+SILVER INC. CA15643T6025 CENTURION MINERALS L. NEW CA52475E1060 LEGIBLE INC. CA60306F1018 MINERAL ROAD DISC. O.N. CA62849F2008 MYDECINE INNOVAT.GRP CA65345P1018 NEXUS URANIUM CORP. US00653A1079 ADAPTH.TH.SP.ADR6 DL-,001 US98888T1079 ZIMVIE INC. DL -,01...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA01559R4008 Algernon Pharmaceuticals Inc. 21.10.2025 CA01559C1068 Algernon Pharmaceuticals Inc. 22.10.2025 Tausch 1:1 CA62849F2008 Mydecine Innovations Group Inc. 21.10.2025 CA62849F4087 Mydecine Innovations Group Inc. 22.10.2025 Tausch 50:1 CA0682943059 Baroyeca Gold & Silver Inc. 21.10.2025 CA98956K1030 0749116 B C Ltd. 22.10.2025 Tausch 14:1 CA15643T6025 Centurion Minerals Ltd. 21.10.2025 CA15643T7015 Centurion Minerals Ltd. 22.10.2025 Tausch 4:1 CA60306F1018 Mineral Road Discovery Inc. 21.10.2025 CA60306F2008 Mineral Road Discovery Inc. 22.10.2025 Tausch 3:1 CA65345P1018 Nexus Uranium Corp. 21.10.2025 CA65345P2008 Nexus Uranium Corp. 22.10.2025 Tausch 10:1...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL MYDECINE INNOVAT.GRP 0NF0 CA62849F2008 BAW/UFN...

Instrument ID [11073828] (0NF0 - CA62849F2008) suspended...

Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Mydecine Innovations Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) ......

  Vancouver, British Columbia, October 14, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has closed the previously announced debt settlement agreements (the “Settlements Agreements”) to settle outstanding debts totaling USD$1,386,391 and CAD$9,432,107 owed to certain arm's length creditors and a non-arm length creditor (the “Creditors”) of the Company for unpaid invoices, management fees, and unpaid convertible debenture. Pursuant to the Settlement Agreements, the Company has issued five convertible debentures (the “Debentures”) to the Creditors (the “Debt Settlements”) with details set out below. The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debts by the issuance of the Debentures in order to preserve the Company's cash for working capital and to improve the Company's financial situation. At the Meeting, ...

  Vancouver, British Columbia, October 6, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the results of voting at its annual general and special meeting of shareholders (the “Shareholders”) held on October 1, 2025 (the “Meeting”). At the Meeting, Shareholders approved all resolutions set forth in the Company's management information circular dated August 20, 2025 (the “Circular”). Disinterested Shareholders also approved all related party transactions, with the same votes excluded as required under the minority approval provisions of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Debt Settlements with Related Parties At the Meeting, disinterested Shareholders approved the settlement of certain debts with related parties through the issuance of convertible debentures, as follows: a) USD Settlement Agreements The Company entered into deb...

Vancouver, British Columbia, June 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement"). The Company reports that the audit is progressing and it expects to file the Annual Filings by June 30, 2025. The Company is also progressing on completion of its interim financial statements and accompanying management's ...

Vancouver, British Columbia – TheNewswire - June 12, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement"). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about June 26, 2025. The Company is also progressing on completion of its interim financial st...

Vancouver, British Columbia – TheNewswire - May 29, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement"). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about June 12, 2025. The Company is also progressing on completion of its interim financial sta...

Vancouver, British Columbia – TheNewswire - May 15, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement"). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about May 29, 2025. The Company is also progressing on completion of its interim financial stat...

Vancouver, British Columbia, May 01, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) announces today that as a result of delays to its audit, the Company's annual financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the “Annual Filings”), the Company has determined that they may not be able to file the Required Filings by the Filing Deadline as required by Part 4 of National Instrument 51-102 Continuous Disclosure Obligations. The reason for the anticipated delay is primarily due to the late commencement of the audit process, which was caused by the Company's financial constraints. These constraints resulted in outstanding fees owed to the external auditor for the prior year's audit. As a result, the Company was unable to engage its auditor to commence the audit for the current year. In addition, a recent change in management further impacted the timing of the audit pr...

Vancouver, British Columbia, March 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter Field to its board of directors, effective March 18, 2025. Mr. Field is a seasoned entrepreneur with over 30 years of experience in business development, product innovation, and leadership. Based in Vancouver, he has been involved in ventures leveraging advanced technologies, including an AI-driven vertical farming platform and pharmaceutical commercialization. He has helped build and manage two GMP, USFDA-certified manufacturing facilities and has invested in biotech companies focused on wound care, Alzheimer's, depression, and cancer biomarkers. More recently, as President of a biotech company, Mr. Field has as gained extensive experience in public markets, capital raises, and regulatory compliance, playing a pivotal role in securing funding and guiding corporate governance. In addition, the Company h...

Delisting From AQSE Vancouver, British Columbia, 21 March 2025 - Mydecine Innovations Group Inc. (the "Company") (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that, further to the announcement of 10 October 2024, its common shares will be withdrawn from trading on the Aquis Stock Exchange Growth Market with effect from market open on 2 April 2025.  Consequently, the last day of trading will be 1 April 2025 however the common shares will remain trading on the CSE, OTC and FSE.   The Directors of Mydecine take responsibility for this announcement.   This...

SUSPENSION OF TRADING Vancouver, British Columbia, 10 October 2024— Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that its shares have been suspended from trading on the Aquis Growth Market for failure to pay exchange fees pursuant to Rule 3.10 of the Aquis Stock Exchange Rulebook (Access) with effect from today, 10/10/2024.   The Directors of Mydecine take responsibility for this announcement. This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as...